New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
NCT ID NCT06239272
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 4 times
Summary
This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their risk level, and some also get targeted radiation. The goal is to control the disease and prevent it from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADIPOCYTIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30329, United States
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
-
Our Lady of the Lake Children's Hospital
RECRUITINGBaton Rouge, Louisiana, 70809, United States
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Email: •••••@•••••
-
Washington University Medical Center
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can a new drug shrink Hard-to-Treat childhood cancers?
- Could a genetic marker guide future cancer therapies in taiwan?
- Experimental drug targets rare cancer that often defies treatment
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Experimental drug opens door for rare sarcoma patients with no options left